More than 5,000 potentially life-changing treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast reservoir…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion
Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Pioneer Novel Genetic Medicines for Kidney Diseases
Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX Therapeutics have significantly expanded their strategic research and licensing collaboration, aiming to pioneer the development of…
Read More
Cellares, TScan to assess automated manufacturing of TSC-101 therapy
In a significant development poised to accelerate the accessibility of cutting-edge cell therapies, Cellares and TScan Therapeutics have announced a…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Revolutionize Kidney Disease Treatment Through Advanced Genetic Medicine
Eli Lilly and Company has announced a significant research collaboration and licensing agreement with Ascidian Therapeutics, a pioneering biotechnology firm…
Read More
ASCO 2026: Navigating the Evolving Landscape of Non-Small Cell Lung Cancer with Promising Data from Eli Lilly and Mixed Reactions for Summit/Akeso
The American Society of Clinical Oncology (ASCO) 2026, held from May 29 to June 2, 2026, served as a critical…
Read More
FDA Grants Priority Review to Roche’s Giredestrant for Early-Stage Breast Cancer, Signaling Potential Paradigm Shift in Adjuvant Therapy
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational…
Read More
European Commission Approves AbbVie’s Aquipta (atogepant) for Acute Migraine Treatment
AbbVie has secured a significant regulatory endorsement from the European Commission (EC) for Aquipta (atogepant), marking a pivotal expansion of…
Read More
